Ebola vaccine uptake and attitudes among healthcare workers in North Kivu, Democratic Republic of the Congo, 2021.
Democratic Republic of the Congo
Ebola
Ebola vaccine
Ebola virus disease (EVD)
vaccine acceptance
vaccine hesitancy
vaccines
Journal
Frontiers in public health
ISSN: 2296-2565
Titre abrégé: Front Public Health
Pays: Switzerland
ID NLM: 101616579
Informations de publication
Date de publication:
2023
2023
Historique:
received:
26
10
2022
accepted:
19
06
2023
medline:
11
8
2023
pubmed:
10
8
2023
entrez:
10
8
2023
Statut:
epublish
Résumé
During the 2018-2020 Ebola virus disease (EVD) outbreak in the eastern part of the Democratic Republic of the Congo (DRC), prevention and control measures, such as Ebola vaccination were challenging by community mistrust. We aimed to understand perceptions regarding Ebola vaccination and identify determinants of Ebola vaccine uptake among HCWs. In March 2021, we conducted a cross-sectional survey among 438 HCWs from 100 randomly selected health facilities in three health zones (Butembo, Beni, Mabalako) affected by the 10th EVD outbreak in North Kivu, DRC. HCWs were eligible if they were ≥ 18 years and were working in a health facility during the outbreak. We used survey logistic regression to assess correlates of first-offer uptake (i.e., having received the vaccine the first time it was offered vs. after subsequent offers). Of the 438 HCWs enrolled in the study, 420 (95.8%) reported that they were eligible and offered an Ebola vaccine. Among those offered vaccination, self-reported uptake of the Ebola vaccine was 99.0% (95% confidence interval (CI) [98.5-99.4]), but first-offer uptake was 70.2% (95% CI [67.1, 73.5]). Nearly all HCWs (94.3%; 95% CI [92.7-95.5]) perceived themselves to be at risk of contracting EVD. The most common concern was that the vaccine would cause side effects (65.7%; 95% CI [61.4-69.7]). In the multivariable analysis, mistrust of the vaccine source or how the vaccine was produced decreased the odds of first-time uptake. Overall uptake of the Ebola vaccine was high among HCWs, but uptake at the first offer was substantially lower, which was associated with mistrust of the vaccine source. Future Ebola vaccination efforts should plan to make repeated vaccination offers to HCWs and address their underlying mistrust in the vaccines, which can, in turn, improve community uptake.
Identifiants
pubmed: 37559741
doi: 10.3389/fpubh.2023.1080700
pmc: PMC10408297
doi:
Substances chimiques
Ebola Vaccines
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
1080700Subventions
Organisme : NIAID NIH HHS
ID : R25 AI140490
Pays : United States
Informations de copyright
Copyright © 2023 Doshi, Garbern, Kulkarni, Perera, Fleming, Muhayangabo, Ombeni, Tchoualeu, Kallay, Song, Powell, Gainey, Glenn, Mutumwa, Hans Bateyi Mustafa, Earle-Richardson, Gao, Abad, Soke, Fitter, Hyde, Prybylski, Levine, Jalloh and Mbong.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Glob Health Sci Pract. 2021 Jul 1;9(2):332-343
pubmed: 34234025
Vaccine. 2014 Apr 17;32(19):2150-9
pubmed: 24598724
Vaccines (Basel). 2021 May 17;9(5):
pubmed: 34067682
MMWR Morb Mortal Wkly Rep. 2014 Nov 21;63(46):1077-81
pubmed: 25412067
Emerg Infect Dis. 2022 Jun;28(6):1180-1188
pubmed: 35608607
BMC Public Health. 2016 Nov 8;16(1):1140
pubmed: 27821112
Can Pharm J (Ott). 2021 Apr 19;154(3):133-135
pubmed: 34104261
N Engl J Med. 2019 Jul 25;381(4):373-383
pubmed: 31141654
Future Microbiol. 2020 Jan;15:85-106
pubmed: 32030996
Vaccine. 2019 Apr 10;37(16):2174-2178
pubmed: 30878249
PLoS Negl Trop Dis. 2016 Aug 18;10(8):e0004802
pubmed: 27537602
Lancet. 2018 Oct 20;392(10156):1399-1401
pubmed: 30297137
Vaccine. 2019 Nov 15;37(48):7190-7200
pubmed: 28890191
PLoS One. 2020 Apr 27;15(4):e0230406
pubmed: 32339195
Vaccine. 2015 Aug 14;33(34):4215-7
pubmed: 25896378
Vaccine. 2014 Aug 27;32(38):4860-5
pubmed: 24262311
Lancet. 2017 Feb 4;389(10068):505-518
pubmed: 28017403
Glob Health Sci Pract. 2020 Dec 23;8(4):638-653
pubmed: 33361232
Vaccine. 2020 May 8;38(22):3854-3861
pubmed: 32291102
PLoS One. 2021 Nov 3;16(11):e0258871
pubmed: 34731208
Hum Vaccin Immunother. 2018;14(10):2391-2396
pubmed: 29923787
MMWR Morb Mortal Wkly Rep. 2014 Dec 12;63(49):1168-71
pubmed: 25503921
Lancet. 2018 Mar 17;391(10125):1021
pubmed: 29565013
BMJ Glob Health. 2017 Dec 04;2(4):e000285
pubmed: 29259820
Science. 2019 Jan 18;363(6424):213-214
pubmed: 30655420
N Engl J Med. 2022 Jul 7;387(1):58-65
pubmed: 35767527
BMJ Glob Health. 2021 Aug;6(8):
pubmed: 34413078
J Glob Health. 2022 Feb 26;12:04006
pubmed: 35265325
Vaccine. 2016 Dec 20;34(52):6700-6706
pubmed: 27810314
Vaccine. 2017 Dec 14;35(49 Pt B):6915-6923
pubmed: 28716555
Lancet Infect Dis. 2019 May;19(5):529-536
pubmed: 30928435
MMWR Morb Mortal Wkly Rep. 2017 Oct 20;66(41):1109-1115
pubmed: 29049279
MMWR Morb Mortal Wkly Rep. 2021 Dec 17;70(50):1723-1730
pubmed: 34914669
Clin Infect Dis. 2019 Jan 7;68(2):330-333
pubmed: 29961823
Vaccine. 2019 Nov 15;37(48):7165-7170
pubmed: 31623917
PLoS One. 2019 Sep 26;14(9):e0223104
pubmed: 31557243
Vaccine. 2012 May 21;30(24):3541-5
pubmed: 22475859
PLoS One. 2020 Oct 22;15(10):e0241120
pubmed: 33091054
Vaccine. 2018 Sep 5;36(37):5617-5624
pubmed: 30087047
Clin Trials. 2016 Feb;13(1):49-56
pubmed: 26768572
Vaccine. 2013 Aug 20;31(37):3972-8
pubmed: 23777954